• 1
    Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347354.
  • 2
    Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003; 98: 20602063.
  • 3
    Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212220.
  • 4
    Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655661.
  • 5
    Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203213.
  • 6
    Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis 2000; 182: 15881594.
  • 7
    Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91: 4647.
  • 8
    Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol 1995; 142: 331341.
  • 9
    Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–1996. Addiction 2001; 96: 589595.
  • 10
    Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 271: 115120.
  • 11
    Atkinson J, Edlin BR, Engels EA, Kral AH, Seal K, Gamache CJ, et al. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis 2003; 187: 974981.
  • 12
    Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001; 357: 13971401.
  • 13
    Kral AH, Lorvick J, Gee L, Bacchetti P, Rawal B, Busch M, et al. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987–1998. Am J Epidemiol 2003; 157: 915922.
  • 14
    Breslow N, Day N. The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
  • 15
    Stokes M, Davis C, Koch G. Categorical data analysis using the SAS® system. 2nd ed. Cary, NC: SAS Institute; 2000.
  • 16
    Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 32743277.
  • 17
    Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001; 127: 475484.
  • 18
    Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. HEPATOLOGY 2001; 34: 180187.
  • 19
    Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1): S11S19.
  • 20
    Diaz T, Des Jarlais DC, Vlahov D, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 912330.
  • 21
    Edlin BR. Prevention and treatment of hepatitis C in injection drug users. HEPATOLOGY 2002; 36(5 Suppl 1 ): S210S219.
  • 22
    Edlin BR. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy 2004; 15: 8191.
  • 23
    Wright NM, Millson CE, Tompkins CN. What is the evidence for the effectiveness of interventions to reduce hepatitis C infection and the associated morbidity? A Health Evidence Network Report. Copenhagen: WHO, 2005. Available at:; accessed May 7, 2007.
  • 24
    Seal KH, Kral AH, Lorvick J, McNees A, Gee L, Edlin BR. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003; 71: 127131.
  • 25
    Gerstein DR, Lewin LS. Treating drug problems. N Engl J Med 1990; 323: 844848.